Table 2. Summary of the clinical application of MSCs.
| Disease | Sample size | Study period |
MSCs |
Stage | Reference | ||
|---|---|---|---|---|---|---|---|
| Source of MSCs | Dosagea | Effect | |||||
| Acute and chronic GvHD | 18 Adults | 3 Days to 1 year | Allogeneic BM-MSCs | 1–2 × 106/kg, 1 dose | Y | Phase I/II | 82 |
| GvHD | 20 Adults | 1 Year | Allogeneic BM-MSCs | / | Y | / | 84 |
| GvHD | 3 Adults | 20–103 Days | Allogeneic BM-MSCs | 0.5 × 106/kg, 1 dose | Y | / | 85 |
| GvHD | 12 Adults | 795–1914 days | Allogeneic BM-MSCs | 0.4 –1.1 × 106/kg, 3 doses | Y | / | 46 |
| Sclerodermatous chronic GvHD | 4 Adults | 4.6–23 Months | Allogeneic BM-MSCs | 1–2 × 107, 1 dose | Y | / | 86 |
| GvHD | 32 Adults | 28 Days | Allogeneic BM-MSCs | 2 or 8 × 106/kg, 1 dose | Y | / | 87 |
| GvHD | 55 Adults | 60 Months | Allogeneic BM-MSCs | 0.4–9 × 107, 1–5 doses | Y | Phase II | 81 |
| GvHD | 7 Children | 29 Months | Allogeneic BM-MSCs | 0.4–3 × 106/kg, 1 dose | Y | / | 83 |
| GvHD | 8 Adults | 3 Years | Allogeneic BM-MSCs | 1(0.7–9) × 106/kg, 1–2 doses | Y | / | 88 |
| Multiple sclerosis | 10 Adults | 10 Months | Autogenous BM-MSCs | / | Y | Phase IIA | 90 |
| Multiple sclerosis | 8 Adults | / | Autogenous BM-MSCs | 2 × 106/kg, 1 dose | Y | / | 155 |
| Multiple sclerosis | 7 Adults | 6 Months | BM-MSCs | 2 × 107, 1 dose | Y | / | 156 |
| Multiple sclerosis | 10 Adults | 1 Year | Autologous BM-MSCs | 1–2 × 106/kg, 1 dose | Y | Phase IIA | 89 |
| Multiple sclerosis and amyotrophic lateral sclerosis | MS: 15 adults, ALS: 19 adults | 6 Months | Autologous BM-MSCs | MS: 6.32 × 107; ALS: 1.74 × 107, 1 dose | Y | Phase I/II | 91 |
| Multiple sclerosis | 10 Adults | 12 Months | Autogenous BM-MSCs | 3–5 × 107, 1 dose | Y | Phase I | 92 |
| Multiple sclerosis | 10 Adults | 13–26 Months | Autologous BM-MSCs | 8.73 × 106, 1 dose | Y | / | 133 |
| Multiple sclerosis | 15 Adults | 12 Months | Autogenous BM-MSCs | 1–2 × 106/kg, 1 dose | Y | Phase II | 157 |
| Multiple sclerosis | 16 Adults | 6 Months | Placenta MSCs | 15–60 × 107, 1 dose | Y | Phase IB | 158 |
| Kidney transplantation | 159 Adults | 1 Year | Autogenous BM-MSCs | 1–2 × 106/kg, 1 dose | Y | / | 159 |
| Kidney transplantation | 2 Adults | 360 Days | Autologous BM-MSCs | 1.7 or 2 × 106/kg, 1 dose | Y | / | 160 |
| Kidney transplantation | 4 Adults | 540 Days | Autologous BM-MSCs | 2 × 106/kg, 1 dose | Y | Phase I/II | 100 |
| Kidney transplantation | 6 Adults | 6 Months | Autologous BM-MSCs | 1 × 106/kg, 2 doses | Y | Phase I | 161 |
| Type II Diabetes | 10 Adults | 3 Months | Allogeneic placenta-derived MSCs | 1.35 × 106/kg, 1 dose | Y | Phase I | 162 |
| Diabetes | 41 Adults | 2 Years | Autologous BM-MSCs | Intramuscular. No clear statement for dosage | Y | / | 96 |
| Osteoarthritis | 4 Adults | 1 Year | Autogenous BM-MSCs | 8–9 × 106, injected in the knee | N | / | 163 |
| Crohn's disease | 12 Adults | 12 Months | Autogenous BM-MSCs | 2 × 107 at 4-week intervals, injected into the lumen and the wall of the tracks | Y | / | 97 |
| Crohn's disease | 5 Adults | 12–30 Months | Autologous ASCs | 3–30 × 106 injected into the wall of the tracks | N | Phase I | 98 |
| Crohn's disease | 9 Adults | 6 Weeks | Autologous BM-MSCs | 1–2 × 106/kg, 2 doses | Y | Phase I | 106 |
| Crohn's disease | 12 Adults | 2 Years | Human placenta-MSCs | 2–8 × 108/person, 2 doses | Y | Phase I | 164 |
| Crohn's disease | 16 Adults | 6 Weeks | Allogeneic MSCs | 2 × 106/kg, 4 doses | Y | Phase II | 165 |
| SLE | 15 Adults | 17.2±9.5 Months | Autogenous MSCs | 1 × 106/kg, 1 dose | Y | / | 166 |
| SLE | 4 Adults | 12–18 Months | Allogeneic BM-MSCs | ≥1 × 106/kg, 1 dose | Y | / | 65 |
| Ulcerative colitis | 40 Adults | / | Allogeneic BM-MSCs | 1.5 × 108, 1 dose | Y | / | 99 |
Abbreviations: BM-MSC, bone marrow-derived mesenchymal stem cell; GvHD, graft versus host disease; SLE, systemic lupus erythematosus; Y, effect was shown; N, effect was not shown
a
MSCs were administrated intravenously except the special statement